We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

1 hedge funds and large institutions have $71K invested in Viridian Therapeutics in 2014 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
EEG
E.E. Geduld
+$77.7K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
EEG
1
E.E. Geduld
$71K +$77.7K +44 New

VRDN Hedge Fund Activity: Q2 2014 in Review

1 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2014, worth a combined $71K.

Buyers outnumbered sellers: 1 fund opened new VRDN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was E.E. Geduld, opening a new position worth an estimated $77.7K.

  • 1 institutional investor held Viridian Therapeutics (VRDN) as of Q2 2014, up from 0 in Q1 2014.
  • Funds reported $71K of Viridian Therapeutics stock for Q2 2014.
  • 1 fund opened new Viridian Therapeutics positions in Q2 2014 and 0 closed out, a net change of +1 holder.
  • The largest Viridian Therapeutics buyer in Q2 2014 was E.E. Geduld, an estimated $77.7K added.

Based on aggregated 13F filings for Q2 2014.